

Anti-CD3 & SSTR2 Antibody (Tidutamab)

Introduction

Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting the SSTR2 binding domain and the T cell binding domain (CD3). Tidutamab has an intact Fc domain to maintain a long serum half-life. Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cell-mediated cytotoxicity (RTcC).

Product parameters

Alternative Names	XMAB-18087, SSTR2 X CD3
Target Accession	P07766 & P30874
Target	CD3 & SSTR2
CAS number	2148354-90-7
Molecular Weight	147.36 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	-
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

